# Regeneron will cut the price of its cholesterol-lowering treatment Praluent to $225, down from $537.

*biotech · news · 2026-04-24 · Newsweek*

## Key points

- Regeneron will reduce its Praluent price to $225 from $537 on Trump's TrumpRx website.
- All new Regeneron medicines will receive Most Favored Nation pricing, matching lowest international drug prices.
- Regeneron is the 17th major drugmaker to sign a TrumpRx and MFN deal with the administration.
- Multiple Regeneron medications in clinical trials will also be subject to MFN pricing under this agreement.

**Companies:** Regeneron, Pfizer, AstraZeneca, Eli Lilly and Company, Amgen, Bristol Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Sanofi, AbbVie, Johnson & Johnson
**Countries:** United States

[Read the full story on Newsweek](https://www.newsweek.com/list-of-drugs-that-could-see-massive-price-cuts-under-trump-deal-11872436)

---

Canonical: https://newsio.io/n/ce3c65fa-158e-4cad-8399-02c0c50febf9/regeneron-will-cut-the-price-of-its-cholesterol-lowering-treatment-praluent-to-2
Summarized by Newsio from Newsweek. https://newsio.io/how-it-works